Target intelligence / Profile preview

T-complex protein 1 subunit alpha (TCP1)

Target
TCP1
Molecular classification
Molecular chaperone, Chaperonin, Group II chaperonin (TRiC/CCT complex)
01

Overview

T-complex protein 1 subunit alpha (TCP1) is a molecular chaperone that forms one of the eight distinct subunits of the eukaryotic cytosolic chaperonin-containing TCP1 complex (CCT; also known as the TCP1 ring complex, TRiC)[1][2][4][6]. The TRiC complex features two stacked rings, each composed of eight different CCT subunits, including TCP1, and acts as a folding chamber powered by ATP hydrolysis[1][4]. TCP1/CCT1 is required for proper folding of essential cytoskeletal proteins such as actin and tubulin, as well as for the maturation of many other proteins critical for cell cycle progression, proliferation, and maintenance of cellular structure and signaling[2][5]. CCT/TRiC subunits, including TCP1, have been found upregulated in a variety of tumor types, with dysregulation linked to cancer pathogenesis and poor prognosis[2][7]. The complex is also implicated in other diseases where proteostasis is disrupted, such as certain neurodegenerative disorders. TCP1 is essential for viability in mammals, with knockout or disruption leading to impaired folding of client proteins and cellular dysfunction[1][2][5][10].

Other names
T-complex 1CCT1CCT-alphaCCTaCCT-αTCP-1-alphac-cpn
02

Mechanism of action

Drugs or molecules modulating TCP1/CCT1 function act via disruption of chaperone-mediated folding, affecting client proteins essential for tumor cell proliferation and survival[7][2].

03

Biological functions

Protein foldingCell proliferationCell cycle regulationApoptosisCytoskeletal organizationTelomere maintenanceCiliogenesis
04

Disease associations

CancerNeurodegenerative diseaseOther (dysfunction impacts multiple disorders due to its essential role in protein folding)
05

Safety considerations

Essential for viability in eukaryotic cells since it assists in folding a significant proportion of the proteome (~10%); targeting may cause toxicity in normal proliferating cells, leading to potential therapeutic challenges[2][5][7].
06

Interacting drugs

No FDA-approved drugs are known to directly target TCP1/CCT1; experimental modulators and indirect inhibitors (e.g., modulators of the CCT complex) may exist[7].
07

Biomarkers

Overexpression or dysregulation of CCT/TRiC subunits (including TCP1) is a biomarker of poor prognosis in several cancers (e.g., hepatocellular carcinoma, neuroblastoma, breast, colon, and lung cancer)[2][7].

Beyond the preview

Go deeper on T-complex protein 1 subunit alpha (TCP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-complex protein 1 subunit alpha (TCP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call